79.49
+0.19(+0.24%)
Currency In USD
| Previous Close | 79.3 |
| Open | 78.15 |
| Day High | 80.22 |
| Day Low | 77.92 |
| 52-Week High | 95.32 |
| 52-Week Low | 34.34 |
| Volume | 659,387.89 |
| Average Volume | 940,661 |
| Market Cap | 4.92B |
| PE | -18.36 |
| EPS | -4.33 |
| Moving Average 50 Days | 83.07 |
| Moving Average 200 Days | 66.2 |
| Change | 0.19 |
Apogee Therapeutics to Participate in Upcoming March Conferences
GlobeNewswire Inc.
Feb 24, 2026 12:30 PM GMT
SAN FRANCISCO and BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Tuesday, Marc
Apogee Therapeutics to Participate at the Guggenheim Emerging Outlook: Biotech Summit 2026
GlobeNewswire Inc.
Feb 05, 2026 1:00 PM GMT
SAN FRANCISCO and BOSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday
Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook
GlobeNewswire Inc.
Jan 06, 2026 11:00 AM GMT
Phase 1b interim results of zumilokibart (APG777) in asthma demonstrated rapid and durable suppression of FeNO (key biomarker of Type 2 inflammation) through 16 weeks for all patients - Suppression of FeNO through 32 weeks for patients with available